These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34591356)

  • 61. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Desai AS; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; McCague K; Abbas CA; Rocha R; Mitchell GF;
    JAMA; 2019 Sep; 322(11):1077-1084. PubMed ID: 31475296
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    Vardeny O; Claggett B; Kachadourian J; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2019 Mar; 21(3):337-341. PubMed ID: 30741494
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
    Charuel E; Menini T; Bedhomme S; Pereira B; Piñol-Domenech N; Bouchant S; Boussageon R; Bœuf-Gibot S; Vaillant-Roussel H
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00844. PubMed ID: 34617669
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test.
    Malfatto G; Ravaro S; Caravita S; Baratto C; Sorropago A; Giglio A; Tomaselli M; Parati G; Villani A
    Acta Cardiol; 2020 Dec; 75(8):732-736. PubMed ID: 31577528
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum potassium in the PARADIGM-HF trial.
    Ferreira JP; Mogensen UM; Jhund PS; Desai AS; Rouleau JL; Zile MR; Rossignol P; Zannad F; Packer M; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2020 Nov; 22(11):2056-2064. PubMed ID: 32809261
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
    Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.
    Kim H; Oh J; Lee S; Ha J; Yoon M; Chun KH; Lee CJ; Park S; Lee SH; Kang SM
    Sci Rep; 2021 Aug; 11(1):16335. PubMed ID: 34381126
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
    Krittayaphong R; Permsuwan U
    Clin Drug Investig; 2021 Oct; 41(10):907-915. PubMed ID: 34533783
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
    Lelonek M; Wiśniowska-Śmiałek S; Rubiś P; Nowakowska I; Pawlak A
    Adv Clin Exp Med; 2021 Jan; 30(1):67-75. PubMed ID: 33529509
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
    Lund LH; Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Kalus S; Ferber PC; Koch C; Maggioni AP;
    Int J Cardiol; 2023 Jan; 370():279-286. PubMed ID: 36216094
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    McCormack PL
    Drugs; 2016 Mar; 76(3):387-96. PubMed ID: 26873495
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan.
    Lin PL; Lee YH; Liu LY; Tsai CT; Yang TF; Chiou WR; Hsieh MY; Chang HY; Huang CC
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221107799. PubMed ID: 35713466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
    J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.